|
|
||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Letter |
Massachusetts General Hospital Harvard Medical School Boston, MA 02114
WEB—This is a Web exclusive article.
The low sensitivity is disappointing given that an accurate imaging technique for assessing nodal status in endometrial cancer patients would be a valuable clinical tool. It would enable a surgeon to plan the extent of lymphadenectomy preoperatively to minimize morbidity and sampling error. For patients who have undergone hysterectomy with incomplete operative staging, such a tool could facilitate non invasive assessment of disease extent and might obviate a second operation.
We note that 35% (14/40) of the patients evaluated in this study had tumors of low grade (grade 1 endometrioid histology). This could explain, in part, the observed low sensitivity. The histologic grade of cancer may correlate with FDG avidity.
It would be helpful to know whether PET/CT is more sensitive in patients with higher-grade tumors. The histologic grade of a cancer is often known from the prehysterectomy endometrial biopsy. Because higher-grade tumors are associated with an increased risk of nodal metastases [2], PET/CT might still prove helpful in planning treatment for the subgroup of endometrial cancer patients at greatest risk for nodal spread.
Can the authors analyze their data to illuminate this issue? Does tumor grade influence the performance characteristics of PET/CT?
References
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |